Across TCGA pan-cancer cohorts, H3C13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated H3C13 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher H3C13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H3C13 expression acts as an unfavorable survival marker.

BRCA, GBM, and LGG are the cancer types where H3C13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.110	0.578	.001	24	view →
GBM	OS	Median	All	0.086	0.415	.010	6	view →
LGG	DFS	Median	All	0.192	0.738	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: H3C13 tumor-vs-normal RNA expression · all H3C13 data types